Scientists test CAR-T cells made inside the body to fight Hard-to-Treat myeloma
NCT ID NCT07715630
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This early-phase trial tests a new approach called PICX Injection, a CAR-T cell therapy that is prepared inside the patient's body rather than in a lab. It is for people with multiple myeloma that has returned or not responded to at least two prior treatments. The study will evaluate the safety, tolerability, and any signs that the therapy is working against the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an in vivo prepared CAR-T cell therapy called PICX Injection
- What this could lead to
- If successful, this could lead to a more convenient and potentially effective CAR-T therapy for multiple myeloma that is prepared inside the body.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, so efficacy is uncertain. The therapy may cause severe side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
RECRUITINGKunming, Yunnan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody drug aims to outsmart Treatment-Resistant myeloma
- New hope for Tough-to-Treat blood cancer: phase 3 trial launched
- New Three-Drug cocktail aims to tackle Hard-to-Treat multiple myeloma
- Double-Barreled CAR-T cells take aim at Hard-to-Treat myeloma
- Double-Barreled CAR-T attack on Hard-to-Treat myeloma
- New antibody drug tested for tough blood cancers – but trial stopped early